Citations

Clear

6273 citation(s) found for "To, Andrew".

Effects of Selective Substitution of Cysteine Residues on the Conformational Properties of Chlorotoxin Explored by Molecular Dynamics Simulations
Gregory, Andrew , Voit-Ostricki, Leah, Lovas, Sándor , Watts, Charles R. , Gregory, Andrew J

Mayo Clinic

International Journal of Molecular Sciences | March 14, 2019 | Volume: 20 | Issue: 6 | Pages: 1261

10.3390/ijms20061261 | PMID 30871150 Get It

Chlorotoxin (CTX) is a 36–amino acid peptide with eight Cys residues that forms four disulfide bonds. It has high affinity for the glioma-specific chloride channel and matrix metalloprotease-2. Structural and binding properties of CTX analogs with various Cys residue substitutions with l-α-aminobutyric acid (Abu) have been previously reported. Using 4.2 µs molecular dynamics, we compared the conformational and essential space sampling of CTX and analogs with selective substitution of the Cys residues and associated disulfide bonds with either Abu or Ser. The native and substituted peptides maintained a high degree of α-helix propensity from residues 8 through 21, with the exception of substitution of the Cys5–Cys28 residues with Ser and the Cys16–Cys33 residues with Abu. In agreement with previous circular dichroism spectropolarimetry results, the C-terminal β-sheet content varied less from residues 25 through 29 and 32 through 36 and was well conserved in most analogs. The Cys16–Cys33 and Cys20–Cys35 disulfide-bonded residues appear to be required to maintain the αβ motif of CTX. Selective substitution with the hydrophilic Ser, may mitigate the destabilizing effect of Cys16–Cys33 substitution through the formation of an inter residue H-bond from Ser16:OγH to Ser33:OγH bridged by a water molecule. All peptides shared considerable sampled conformational space, which explains the retained receptor binding of the non-native analogs.
Comparison of the NCCN‐IPI, the IPI and PIT scores as prognostic tools in peripheral T‐cell lymphomas
Ellin, Fredrik , Maurer, Matthew J. , Srour, Line, Farooq, Umar , Smedby, Karin E. , Ansell, Stephen M. , Slack, Graham W. , Relander, Thomas, Cerhan, James R , Savage, Kerry J , Maurer, Matthew , Farooq, Umar , Jerkeman, Mats , Connors, Joseph M. , Bennani, N. Nora , Cerhan, James R. , Feldman, Andrew L. , Savage, Kerry J.

Mayo Clinic

British Journal of Haematology | March 12, 2019 | Volume: 186 | Issue: 3 | Pages: No page available

10.1111/bjh.15859 | PMID 30859549 Get It

Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF).
Egyed, Miklós , Szőke, Anita , Suvorov, Aleksandr , Mayer, Jiří , Jourdan, Éric , Schouten, Harry C. , Tosi, Patrizia , Dean, James , Cernohous, Paul, Nangalia, Jyoti , Harrison, Claire , Mesa, Ruben A. , Perkins, Andrew C. , Ganly, Peter S. , Farber, Charles Michael , Zachée, Pierre , Scheid, Christof , Kiladjian, Jean‐Jacques , Vannucchi, Alessandro M. , Mead, Adam J.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: LBA7006-LBA7006

10.1200/jco.2015.33.15_suppl.lba7006 Get It

Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.
Ahmad, Syed A. , Marsh, Robert , Collisson, Eric A. , Schwartz, Lawrence H., Martin, Robert C.G. , Conway, William, Truty, Mark J. , Kindler, Hedy L. , Lowy, Andrew M. , Philip, Philip Agop, Cardin, Dana B. , LoConte, Noelle K. , Cardin, Dana B , LoConte, Noelle , Katz, Matthew H. G. , Shi, Qian , Herman, Joseph M. , Bekaii‐Saab, Tanios , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4008-4008

10.1200/jco.2015.33.15_suppl.4008 Get It

A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.
Ko, Andrew H. , Chiorean, E. Gabriela , Kwak, Eunice L., Lenz, Heinz‐Josef , Nadler, Paul I., Wood, Debra L., Fujimori, Masamoto, Morita, Kohei , Inada, Tetsuhi, Kouji, Hiroyuki , McWilliams, Robert R. , Fujimori, Masamoto

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e15270-e15270

10.1200/jco.2015.33.15_suppl.e15270 Get It

Identifying predictive biomarkers for metastatic progression in stage I and II clear cell renal cell carcinoma.
Murphy, Neal , Shih, Andrew , Kozel, Zachary , Shah, Paras , Yaskiv, Oksana, Khalili, Houman , Liew, Anthony, Kavoussi, Louis R., Hall, Simon J. , Vira, Manish , Lee, Annette , Zhu, Xinhua , Khalili, Houman

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: 631-631

10.1200/jco.2019.37.7_suppl.631 Get It

631 Background: For most clear cell renal cell carcinoma (ccRCC) patients with early stage disease, surgical resection offers definitive cure. However, for the small percentage of tumors that metastasize, analyzing gene expression profiles from the primary site at the time of nephrectomy can serve as a model to understand the molecular aberrations behind a metastatic phenotype. Differences in gene expression profiles between patients with Stage I and II ccRCC who experience metastasis versus patients who maintain cure after surgery may help elucidate significant molecular targets and stratify patients at higher risk for metastasis. Methods: Nineteen Stage I and twenty Stage II ccRCC tumors preserved in FFPE blocks after nephrectomy were included in this study. Patients were matched for age, gender, tumor size and grade. In both stages, approximately half the patients that experienced metastasis within 5 years of surgery were part of the experimental group, whereas the control group had > 5 years of follow-up without evidence of disease. Extracted RNA for Stage I patients was sequenced using Illumina TruSeq RNA Access Library. Gene counts were assessed by ht-seq counts and differential expression using DESeq2. Significant genes found were validated in the Stage II group using RT-qPCR. Results: In the Stage I experimental group, statistically significant upregulation of several genes associated with unfavorable prognosis in RCC were found: COL1A1, NUMBL, and STEAP3. Random forest classification accurately separated Stage I control versus experimental patients based on expression of COL1A1. Affected genes were consistent with molecular changes seen in TCGA analysis. In the Stage II group, a double-blinded analysis correctly identified the clinical outcome for the majority of the patients using qPCR expression of COL1A1, NUMBL, and STEAP3. Conclusions: Differences in gene expression profiles harbored in the primary site of early stage ccRCC may be employed to predict patients at high risk for developing metastasis. Validating these findings in a larger study carries the potential to better understand mechanisms of metastasis and identify an at risk cohort of patients with early stage disease.
Epidemiology of Cervical Injuries in NCAA Football Players
Chung, Andrew S. , Makovicka, Justin L. , Patel, Karan A. , Deckey, David G. , Hydrick, Thomas C. , Rubel, Nicholas , Hassebrock, Jeffrey D. , Rubel, Nicolas C, Patel, Karan , Chung, Andrew , Tummala, Sailesh V , Tummala, Sailesh V. , Chhabra, Anikar

Mayo Clinic

Spine | March 7, 2019 | Volume: 44 | Issue: 12 | Pages: 848-854

10.1097/brs.0000000000003008 | PMID 30830045 Get It

Study Design. Descriptive epidemiology study. Objective. The purpose of this study was to describe the epidemiology of cervical spine injuries in collegiate football players. Summary of Background Data. The incidence and etiology of cervical spine injuries in National Collegiate Athletic Association (NCAA) football players has not been well defined in recent years. Methods. The incidence and characteristics of cervical spine injuries were identified utilizing the NCAA-ISP database. Rates of injury were calculated as the number of injuries divided by the total number of athlete-exposures (AEs). AEs were defined as any student participation in one NCAA-sanctioned practice or competition. Results. An estimated 7496 cervical spine injuries were identified. Of these, 85.6% were categorized as new injuries. These occurred at a rate of 2.91 per 10000 AEs. Stingers were most common (1.87 per 10000 AEs) followed by cervical strains (0.80 per 10000 AEs). Injuries were nine times more likely to occur during competition when compared with practice settings. When compared with the regular season, the relative risks of sustaining a cervical spine injury during the preseason and postseason were 0.69 (95% CI 0.52–0.90) and 0.39 (95% CI 0.16–0.94), respectively. The rate of cervical spine injuries was highest in Division I athletes. Direct contact-related injuries were most common, representing 90.8% of all injuries sustained. Injuries were most common in linebackers (20.3%) followed secondarily by defensive linemen (18.2%). Most players returned to play within 24 hours of the initial injury (64.4%), while only 2.8% remained out of play for > 21 days. Conclusion. Fortunately, the rate of significant and disabling cervical spine injuries appears to be low in the NCAA football athlete. The promotion of safer tackling techniques, appropriate modification of protective gear, and preventive rehabilitation in these aforementioned settings is of continued value. Level of Evidence: 4
Bias-corrected estimates of reduction of post-surgery length of stay and corresponding cost savings through the widespread national implementation of fast-tracking after liver transplantation: a quasi-experimental study
Loh, Chung-Ping A., Croome, Kristopher P. , Croome, Kris P , Taner, C. Burcin , Keaveny, Andrew P.

Mayo Clinic

Journal of Medical Economics | March 7, 2019 | Volume: 22 | Issue: 7 | Pages: 684-690

10.1080/13696998.2019.1592179 | PMID 30841773 Get It

90-day Readmission in Elective Primary Lumbar Spine Surgery in the Inpatient Setting
Rubel, Nicholas , Chung, Andrew S. , Wong, Michael S. , Lara, Nina , Makovicka, Justin L. , Cho, Samuel , Chang, Michael S., Cho, Samuel K. , Rubel, Nicolas C, Wong, Michael, Lara, Nina J, Chung, Andrew , Wong, Michael, Chang, Michael S.

Mayo Clinic

Spine | March 3, 2019 | Volume: 44 | Issue: 14 | Pages: E857-E864

10.1097/brs.0000000000002995 | PMID 30817732 Get It

Study Design. Secondary analysis of a large administrative database. Objective. The objectives of this study are to: 1) identify the incidence and cause of 90-day readmissions following primary elective lumbar spine surgery, 2) offer insight into potential risk factors that contribute to these readmissions, and 3) quantify the cost associated with these readmissions. Summary of Background Data. As bundled-payment models for the reimbursement of surgical services become more popular in spine, the focus is shifting toward long-term patient outcomes in the context of 90-day episodes of care. With limited data available on national 90-day readmission statistics available, we hope to provide evidence that will aid in the development of more cost-effective perioperative care models. Methods. Using ICD-9 coding, we identified all patients 18 years of age and older in the 2014 Nationwide Readmissions Database (NRD) who underwent an elective, inpatient, primary lumbar spine surgery. Using multivariate logistic regression, we identified independent predictors of 90-day readmission while controlling for a multitude of confounding variables and completed a comparative cost analysis. Results. We identified 169,788 patients who underwent a primary lumbar spine procedure. In total 4268 (2.5%) were readmitted within 90 days. There was no difference in comorbidity burden between cohorts (readmitted vs. not readmitted) as quantified by the Elixhauser Comorbidity index. Independent predictors of increased odds of 90-day readmission were: anemia, uncomplicated diabetes and diabetes with chronic complications, surgical wound disruption and acute myocardial infarction at the time of the index admission, self-pay status, and an anterior surgical approach. Implant complications were identified as the primary related cause of readmission. These readmissions were associated with a significant cost increase. Conclusion. There are clearly identifiable risk factors that increase the odds of hospital readmission within 90 days of primary lumbar spine surgery. An overall 90-day readmission rate of 2.5%, while relatively low, carries significantly increased cost to both the patient and hospital. Level of Evidence: 3
Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post–kidney Transplantation: A Consecutive Series of 15 Cases
Tan, Ek Khoon , Bentall, Andrew , Dean, Patrick G. , Shaheen, Mohammed F. , Stegall, Mark D. , Stegall, Mark D , Bentall, Andrew , Schinstock, Carrie A.

Mayo Clinic

Transplantation | February 28, 2019 | Volume: 103 | Issue: 11 | Pages: 2397-2404

10.1097/tp.0000000000002639 | PMID 30801549 Get It

Background. Active antibody-mediated rejection (AMR) that occurs during the amnestic response within the first month posttransplant is a rare but devastating cause of early allograft loss after kidney transplant. Prior reports of eculizumab treatment for AMR have been in heterogeneous patient groups needing salvage therapy or presenting at varied time points. We investigated the role of eculizumab as primary therapy for active AMR early posttransplant. Methods. We performed a retrospective observational study of a consecutive cohort of solitary kidney transplant recipients who were transplanted between January 1, 2014, and January 31, 2018, and had AMR within the first 30 days posttransplant and treated with eculizumab ± plasmapheresis. Results. Fifteen patients had early active AMR at a median (interquartile range [IQR]) of 10 (7–11) days posttransplant and were treated with eculizumab ± plasmapheresis. Thirteen cases were biopsy proven, and 2 cases were presumed on the basis of donor-specific antibody trends and allograft function. Within 1 week of treatment, the median estimated glomerular filtration rate increased from 21 to 34 mL/min (P = 0.001); and persistent active AMR was only found in 16.7% (2/12) of biopsied patients within 4–6 months. No graft losses occurred, and at last follow-up (median [IQR] of 13 [12–19] mo), the median IQR estimated glomerular filtration rate increased to 52 (46–60) mL/min. Conclusions. Prompt eculizumab treatment as primary therapy is safe and effective for early active AMR after kidney transplant or abrupt increases in donor-specific antibodies when biopsy cannot be performed for diagnosis confirmation.